<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02952937</url>
  </required_header>
  <id_info>
    <org_study_id>GLAPR-106</org_study_id>
    <nct_id>NCT02952937</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Crossover Phase 1 Study to Compare the Pharmacokinetic Characteristics of GLA5PR GLARS-NF1 Tablet 300 mg and GLA5PR GLARS-NF3 Tablet 300 mg in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GL Pharm Tech Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GL Pharm Tech Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to (1) evaluate the bioequivalence(BE) of GLA5PR&#xD;
      GLARS-NF3 tablet 300mg administered regular diet relative to GLA5PR GLARS-NF1 tablet 300mg&#xD;
      administered regular diet and (2) determine the safety and tolerability of a single dose of&#xD;
      GLA5PR GLARS-NF3 tablet 300mg administered regular diet and GLA5PR GLARS-NF1 tablet 300mg&#xD;
      administered regular diet.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the single dose pharmacokinetics, safety, and tolerability of GLA5PR GLARS-NF3&#xD;
      tablet 300mg administered regular diet relative to GLA5PR GLARS-NF1 tablet 300mg administered&#xD;
      regular diet. IP will be administered 1 tablet(300mg) once a day(QD) after evening meal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of Pregabalin</measure>
    <time_frame>Immediately pre-dose(0h), post-dose 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 hr(14 points)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Pregabalin</measure>
    <time_frame>Immediately pre-dose(0h), post-dose 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 hr(14 points)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Pregabalin</measure>
    <time_frame>Immediately pre-dose(0h), post-dose 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 hr(14 points)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Pregabalin</measure>
    <time_frame>Immediately pre-dose(0h), post-dose 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 hr(14 points)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Pregabalin</measure>
    <time_frame>Immediately pre-dose(0h), post-dose 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 hr(14 points)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Pregabalin</measure>
    <time_frame>Immediately pre-dose(0h), post-dose 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 hr(14 points)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Pregabalin</measure>
    <time_frame>Immediately pre-dose(0h), post-dose 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36 hr(14 points)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events, Vital signs, Physical examinations, Clinical safety laboratories and 12-lead EKG.</measure>
    <time_frame>Through study completion(Post-study Visit), an average of 1 month</time_frame>
    <description>Post-study Visit: upto 3 ~7 days after last PK sample collection</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: GLA5PR GLARS-NF1 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).&#xD;
wash-out period: over 7 days.&#xD;
Period 2: GLA5PR GLARS-NF3 tablet 300mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: GLA5PR GLARS-NF3 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).&#xD;
wash-out period: over 7 days.&#xD;
Period 2: GLA5PR GLARS-NF1 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLA5PR GLARS-NF3 tablet 300mg</intervention_name>
    <description>A new formulation(3rd.) of Pregabalin CR tablet</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Test drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLA5PR GLARS-NF1 tablet 300mg</intervention_name>
    <description>A new formulation(1st.) of Pregabalin CR tablet</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Comparator drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects who, at the time of screening, are the age of older than 19&#xD;
             years.&#xD;
&#xD;
          -  Subjects who have BMI more than 17.5kg/m2 and less than 30.5kg/m2 and body weight more&#xD;
             than 55kg.&#xD;
&#xD;
          -  There is no congenital disease or within 3 years of chronic diseases.&#xD;
&#xD;
          -  Healthy is defined as no clinically relevant abnormalities identified by a detailed&#xD;
             medical history, full physical examination, including blood pressure and pulse rate&#xD;
             measurement, 12 lead electrocardiogram (ECG) or clinical laboratory tests.&#xD;
&#xD;
          -  Subjects who signed and dated the informed consent form(approved by IRB) after&#xD;
             understanding fully to hear a detailed explanation in the clinical trial&#xD;
&#xD;
          -  Subjects who are willing and able to comply with all scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or&#xD;
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,&#xD;
             seasonal allergies at the time of dosing).&#xD;
&#xD;
          -  A subject with any history of gastrointestinal disease (e.g., Crohn's disease, acute&#xD;
             or chronic pancreatitis, and others) and surgery (except for simple appendectomy or&#xD;
             repair of a hernia), which can influence the absorption of investigational products.&#xD;
&#xD;
          -  A subject who has the following clinical laboratory test results&#xD;
&#xD;
             ☞ Liver Function Test (AST, ALT) &gt; three times the upper limit of the normal range&#xD;
&#xD;
          -  History of regular alcohol consumption exceeding 210g/week(12g = 125 mL of wine, 10g =&#xD;
             250 mL of beer, 10g = 50 mL of hard liquor) within 6 months of Screening.&#xD;
&#xD;
          -  A subject who has participated in any other clinical trials and had medication within&#xD;
             3 months prior to the first administration of investigational product. (The end date&#xD;
             of another clinical trial is based on the last day of the administration)&#xD;
&#xD;
          -  A subject who has the following vital signs results in sitting position at the time of&#xD;
             the screening :&#xD;
&#xD;
        SBP ≤ 90 mmHg or DBP ≤ 60 mmHg.&#xD;
&#xD;
          -  A subject with a history of drug abuse or a positive urine drug screening for drug&#xD;
             abuse&#xD;
&#xD;
          -  A subject who has taken the drugs that induce and suppress drug-metabolizing enzymes&#xD;
             within 30 days prior to investigational product administration.&#xD;
&#xD;
          -  A smoker who consumes more than 20 cigarettes/days&#xD;
&#xD;
          -  A subject who has taken any ethical-the-counter drug or has taken any over-the-counter&#xD;
             drug within 10days before the investigational product administration&#xD;
&#xD;
          -  A subject who has donated whole blood within 2 months or blood components within 1&#xD;
             month prior to the investigational product administration&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation.&#xD;
&#xD;
          -  A subject who is unable to take regular diet during the study period.&#xD;
&#xD;
          -  Abnormal diet that may affect absorption, distribution, metabolism and excretion of&#xD;
             drugs&#xD;
&#xD;
          -  History of sensitivity to pregabalin, gabapentin, or other alpha2 delta ligands.&#xD;
&#xD;
          -  Evidence of hereditary disease, including galactose intolerance, Lapp lactase&#xD;
             deficiency, or glucose-galactose malabsorption.&#xD;
&#xD;
          -  Unwilling or unable to comply with the Lifestyle Guidelines described in this&#xD;
             protocol.&#xD;
&#xD;
          -  A subject who is not eligible for the study due to reasons on the investigators'&#xD;
             judgment.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Gul Kim, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju-si</city>
        <state>Jeollabuk-do</state>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuralgia, Postherpetic</keyword>
  <keyword>Postherpetic Neuralgia</keyword>
  <keyword>Diabetic Neuropathies</keyword>
  <keyword>Diabetic Neuralgia</keyword>
  <keyword>Diabetic Polyneuropathy</keyword>
  <keyword>Diabetic Neuropathy, Painful</keyword>
  <keyword>Neuralgia</keyword>
  <keyword>Neuropathic Pain</keyword>
  <keyword>Pregabalin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Bioequivalent</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

